iperine for treating breast cancer: A review of molecular mechanisms, combination with anticancer drugs, and nanosystem

Author(s)

Quijia, Christian Rafael ^[1] ; Chorilli, Marlus ^[1]

Affiliation

^[1] Sao Paulo State Univ UNESP, Sch Pharmaceut Sci, Araraquara, SP - Brazil

• Document type: Review article
• Source: Phytotherapy Research; v. 36, n. 1 SEP 2021.
• Web of Science Citations: 1

Abstract

Piperine (PIP) is an alkaloid found primarily in Piper longum, and this natural compound has been shown to exert effects on proliferation and survival against various types of cancer. In particular, PIP has potent inhibitory effects on breast cancer (BC), the most prevalent type of cancer in women worldwide. PIP targets numerous signaling pathways associated with the therapy of BC cells through the following mechanisms: (a) induction of arrest of the cell cycle and apoptosis; (b) alteration of the signaling protein expression; (c) reduction in transcription factors; and (d) inhibition of tumor growth. BC cells have the ability to resist conventional drugs, so one of the strategies is the combination of PIP with other phytochemicals such as paclitaxel, thymoquinone, hesperidin, bee venom, tamoxifen, mitoxantrone, piperlongumin, and curcumin. Nanotechnology-based drug encapsulation systems are currently used to enhance the release of PIP. This includes polymer nanoparticles, carbon nanotubes, and liposomes. In the present review, the chemistry and bioavailability of PIP, its molecular targets in BC, and nanotechnological strategies are discussed. Future research directions are also discussed to further understand this promising natural product. (AU)

• FAPESP's process: 18/21119-0 - Evaluation of the potential of piperine encapsulated in metal-organic frameworks coated with macrophage membranes in the treatment of Breast Cancer
• Grantee: Christian Rafael Quijia Quezada
• Support Opportunities: Scholarships in Brazil - Doctorate